文献速递神经核医学放射性药物与辐射防护

用于定量脑内聚集突变亨廷顿蛋白的PET放射性配体[11C]CHDI-00485180-R与[11C]CHDI-00485626在健康志愿者中的生物分布与剂量学

Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-08-24

本研究在健康志愿者中评估了两种靶向脑内聚集突变亨廷顿蛋白的PET示踪剂[11C]CHDI-180R和[11C]CHDI-626的生物分布与辐射剂量学。每種示踪剂各纳入3名健康志愿者,采用序贯全身PET-CT扫描,用OLINDA 2.1计算器官剂量和有效剂量。结果显示两者均安全,辐射负担与多数11C配体相当;[11C]CHDI-180R脑动力学有前景,而[11C]CHDI-626因可能产生脑内蓄积的放射性代谢物而不适合用于人体mHTT PET。

要点

  • 两种示踪剂在健康志愿者中均未出现临床相关不良事件。
  • [11C]CHDI-180R平均有效剂量为4.58 ± 0.65 μSv/MBq,最高吸收剂量在肝脏(16.9 μGy/MBq)。
  • [11C]CHDI-626因可能产生脑内蓄积的放射性代谢物,不适合用于人体mHTT PET。

核心结论

  • [11C]CHDI-180R和[11C]CHDI-626均可安全用于人体PET显像。
  • 估计的辐射负担与多数11C配体相当。
  • [11C]CHDI-180R脑动力学特性有前景。
  • [11C]CHDI-626因可能产生脑内蓄积的放射性代谢物,不适合用于人体mHTT PET。

研究设计与样本

  • 首次人体研究,在健康志愿者中评估[11C]CHDI-180R和[11C]CHDI-626的生物分布与辐射剂量学。
  • [11C]CHDI-180R组纳入3名健康志愿者(年龄25.7 ± 0.5岁;2名女性)。
  • [11C]CHDI-626组纳入3名健康志愿者(年龄35.3 ± 6.8岁;2名女性)。
  • 采用序贯全身PET-CT扫描,结合PET与CT数据在三维中勾画源器官。
  • 使用OLINDA 2.1确定个体器官剂量和有效剂量。

主要发现

  • 未出现临床相关不良事件。
  • [11C]CHDI-180R平均有效剂量为4.58 ± 0.65 μSv/MBq,最高吸收剂量为肝脏16.9 μGy/MBq、心脏壁15.9 μGy/MBq、小肠15.8 μGy/MBq。
  • [11C]CHDI-626平均有效剂量为5.09 ± 0.06 μSv/MBq,最高吸收剂量为胆囊26.5 μGy/MBq、小肠20.4 μGy/MBq、肝脏19.6 μGy/MBq。
  • 衰减校正后的脑摄取曲线显示[11C]CHDI-180R动力学有前景,而[11C]CHDI-626信号随时间增加,可能由于脑穿透性代谢物蓄积。

关键数值与推荐

  • [11C]CHDI-180R平均有效剂量4.58 ± 0.65 μSv/MBq。
  • [11C]CHDI-626平均有效剂量5.09 ± 0.06 μSv/MBq。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Huntington's disease is caused by a trinucleotide expansion in the HTT gene, which leads to aggregation of mutant huntingtin (mHTT) protein in the brain and neurotoxicity. Direct in vivo measurement of mHTT aggregates in human brain parenchyma is not yet possible. In this first-in-human study, we investigated biodistribution and dosimetry in healthy volunteers of [11C]CHDI-00485180-R ([11C]CHDI-180R) and [11C]CHDI-00485626 ([11C]CHDI-626), two tracers designed for PET imaging of aggregated mHTT in the brain that have been validated in preclinical models. METHODS: Biodistribution and radiation dosimetry studies were performed in 3 healthy volunteers (age 25.7 ± 0.5 years; 2 F) for [11C]CHDI-180R and in 3 healthy volunteers (age 35.3 ± 6.8 years; 2 F) for [11C]CHDI-626 using sequential whole-body PET-CT. Source organs were delineated in 3D using combined PET and CT data. Individual organ doses and effective doses were determined using OLINDA 2.1. RESULTS: There were no clinically relevant adverse events. The mean effective dose (ED) for [11C]CHDI-180R was 4.58 ± 0.65 μSv/MBq, with highest absorbed doses for liver (16.9 μGy/MBq), heart wall (15.9 μGy/MBq) and small intestine (15.8 μGy/MBq). Mean ED for [11C]CHDI-626 was 5.09 ± 0.06 μSv/MBq with the highest absorbed doses for the gallbladder (26.5 μGy/MBq), small intestine (20.4 μGy/MBq) and liver (19.6 μGy/MBq). Decay-corrected brain uptake curves showed promising kinetics for [11C]CHDI-180R, but for [11C]CHDI-626 an increasing signal over time was found, probably due to accumulation of a brain-penetrant metabolite. CONCLUSION: [11C]CHDI-180R and [11C]CHDI-626 are safe for in vivo PET imaging in humans. The estimated radiation burden is in line with most 11C-ligands. While [11C]CHDI-180R has promising kinetic properties in the brain, [11C]CHDI-626 is not suitable for human in vivo mHTT PET due to the possibility of a radiometabolite accumulating in brain parenchyma. TRIAL REGISTRATION: EudraCT number 2020-002129-27. CLINICALTRIALS: gov NCT05224115 (retrospectively registered).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Delva A, Koole M, Serdons K, et al. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin. Eur J Nucl Med Mol Imaging. 2022. PMID: 36001116. doi:10.1007/s00259-022-05945-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。